# A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

> **NCT06091254** · PHASE3 · RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 822 (estimated)

## Conditions studied

- Follicular Lymphoma (FL)

## Interventions

- **DRUG:** Odronextamab
- **DRUG:** Rituximab
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Vincristine
- **DRUG:** Prednisone/prednisolone
- **DRUG:** Bendamustine

## Key facts

- **NCT ID:** NCT06091254
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-12
- **Primary completion:** 2028-02-07
- **Final completion:** 2029-11-03
- **Target enrollment:** 822 (ESTIMATED)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06091254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06091254, "A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT06091254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*